Tag:

WuXi PharmaTech

Latest Headlines

Latest Headlines

WuXi reaches into the biopharma hubs of Boston and San Francisco

WuXi PharmaTech, China's largest CRO, is blueprinting forays into two of the hottest locales for U.S. R&D, planning to open offices in Boston and San Francisco.

WuXi moves to list a subsidiary on the Chinese market

WuXi PharmaTech is moving toward an IPO for one of its R&D and manufacturing subsidiaries, hoping to take advantage of a new market in its native China.

WuXi pairs up with deCODE spinout to further its genomics expansion

WuXi PharmaTech has spent the last year and change amping up its genomics expertise, and now China's largest CRO has signed a deal with Cambridge, MA's NextCODE Health to further grow its bioinformatics offerings.

WuXi ups its revenue ambitions after M&A and expansion

Chinese CRO WuXi PharmaTech is forecasting a better-than-expected 2014 after a strong third quarter and some timely deals, moving into the new year with hopes for continued global growth.

WuXi reaches into Israel with a new office and a local partnership

Chinese CRO WuXi PharmaTech has opened up shop in Israel, cutting the ribbon on a Tel Aviv outpost and aligning itself with a local investor to expand its presence in the country.

WuXi teams up with Foundation Medicine to bring cancer profiling to China

WuXi PharmaTech has struck a deal with the genomics experts at Foundation Medicine, signing on to offer the company's cancer-decoding services to drug developers in its native China.

WuXi snags a stateside CRO to beef up its early-stage services

Chinese CRO WuXi PharmaTech has bought out XenoBiotic Laboratories, a U.S. contractor focused on early-phase research, expanding its North American presence and broadening its lab-based business.

Aldea raises $24M to push alcohol-poisoning antidote to the clinic

Aldea Pharmaceuticals closed a $24 million round of Series B equity financing to support the development of a drug designed to mitigate the severe--and sometimes deadly--effects of alcohol poisoning.

WuXi's manufacturing boom spells a big quarter

WuXi PharmaTech, China's largest CRO, boosted its revenue by 14.8% in the second quarter, as banner growth in its contract manufacturing business helped the company expand its global reach.

WuXi expands its Chinese ops as manufacturing brings in revenue

WuXi PharmaTech has increased its manufacturing capabilities in China, bolstering its fastest-growing business as it looks to expand around the globe.